AAPG: Ascentage Pharma Group International Company Value to Net Income

Ascentage Pharma Group International - graphic logo of issuer AAPG

The high profitability of Ascentage Pharma Group is based on the optimization of biomaterial delivery and supply chain control. The company's P/E ratio clearly demonstrates the balance between actual earnings and market expectations, where -3.70 represents the current level of the metric. However, expansion by global behemoths is creating pressure, forcing the company to seek strategic partners for survival and the development of innovative methods to combat resistant tumors.

Price to Earnings Ratio: Ascentage Pharma Group (AAPG) for 01/25/2025 - 11/13/2026

Comprehensive metric breakdowns and analytics for Ascentage (AAPG)

- share price and expert price forecast:
Price Performance Chart ascentage.com|AAPG - Consensus Target
- market capitalization information:
Market Value Ascentage Pharma Group|AAPG - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Ascentage Pharma|AAPG - Company Net Assets|Market Capitalization to Book Value Ratio ascentage.com|AAPG - Aggregate Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Ascentage Pharma Group|AAPG - Long-Term Debt to Capital|Current Liabilities to Capital Ascentage Pharma Corp|AAPG - Company Aggregate Debts|Debts to Book Capitalization Ascentage Pharma Group|AAPG - Company Long-Term Debt|Short-Term Debt Volume Ascentage Pharma|Quick Liquidity Indicator ascentage.com
- company profitability and valuation multiples indicators:
AAPG - Net Profit|Expected Net Profit Ascentage Pharma Group|AAPG - Price to Earnings Ratio|Price to Future Earnings Ratio Ascentage Pharma Group International|AAPG - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Ascentage Pharma Group|AAPG - Operating profit EBITDA|Net earnings per share (EPS TTM) Ascentage Pharma|AAPG - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year ascentage.com|AAPG - Earnings growth in current year|Expected net earnings per share growth next year Ascentage Pharma Group
Summary company analysis:AAPG, ascentage.com
Flagship merchandise of Ascentage Pharma

The expansion of international trials for leukemia drugs by Ascentage Pharma Group (AAPG) drives the current price-to-earnings ratio dynamics, reflecting market expectations for operating cash flow. This ratio measures the cost per unit of net profit, allowing investors to determine the asset's degree of overheating through mathematical rebalancing and mitigate capital risks in a timely manner, considering the R&D costs already priced in.

Analysis of competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Company Value to Net Income|P/E Multiple CGON (CG Oncology Corp)|URGN - Price to Earnings Ratio|BCAX: Price to Earnings Ratio|PSNL - P/E Multiple|Erasca (ERAS) - Price to Earnings Ratio|Delcath Systems Inc - Company Value to Net Income|YMAB (YmAbs) - P/E Multiple|Market Cap to Earnings Aura Corp AURA|P/E Multiple CADL|P/E Multiple accuray.com (ARAY)|Price to Earnings Ratio SELLAS Life Sciences Group SLS|Business Payback Period Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - P/E Multiple|TuHURA Biosciences, Inc. (HURA) - Price to Earnings Ratio|TARA: P/E Multiple|Market Cap to Earnings fatetherapeutics.com (FATE)|Price to Earnings Ratio Aadi Bioscience, Inc.|Price to Earnings Multiple TCRX (TScan)|Price to Earnings Ratio CSBR (Champions Oncology)|Market Price to Net Income Ratio XBIT|P/E Multiple CVM (CEL-SCI)|P/E Multiple ostherapies.com OSTX|Radiopharm Theranostics - P/E Multiple|Market Cap to Net Income Ratio Artiva Biotherapeutics, Inc. (ARTV)|ANL: P/E Multiple|Market Cap to Earnings Veru Corporation (VERU)|Price to Earnings Ratio TPST|XLO: Company Value to Net Income|Price to Earnings Ratio Renovaro Inc. (RENB)|MURA: Market Cap to Net Income|P/E Multiple KAPA (Kairos Pharma)|Company Value to Net Income OKUR|CytoMed - P/E Multiple|CRIS - P/E Multiple|apollomicsinc.com (APLM) - Price to Earnings Ratio|Tharimmune Inc - Company Value to Net Income|Price to Earnings Ratio Advanced Biomed Inc.|Price to Earnings Ratio Genprex Inc (GNPX)|P/E Multiple CLDI|P/E Multiple sunshinebiopharma.com (SBFM)|Xenetic Biosciences, Inc. - Price to Earnings Ratio|Company Value to Net Income SLRX|Purple Biotech Corp - P/E Multiple|Market Cap to Net Income Ratio American Oncology Network (AONC)|BeiGene, Ltd. (BGNE) - Price to Earnings Ratio|checkpointtx.com - Company Value to Net Income|Price to Earnings Ratio Elevation Oncology|Market Cap to Earnings iCAD Corp ICAD|Price to Earnings Ratio IKNA (Ikena Oncology, Inc.)|P/E Multiple Notable Labs Corp (NTBL)|Price to Earnings Ratio Viracta Therapeutics, Inc. VIRX|MOR (morphosys.com) - Market Cap to Net Income|NAYA Biosciences Inc. - P/E Multiple|AAPGV - P/E Multiple